CAMBRIDGE, Mass.– Alpenglow Biosciences, a leader in AI-powered 3D pathology, has entered a multi-year, milestone-based collaboration with Virdx, a biophysics AI company specializing in MRI-based cancer detection. The partnership aims to accelerate the development of next-generation diagnostic tools that connect radiology and pathology to improve prostate cancer detection and reduce unnecessary interventions.
Virdx’s first focus is enabling radiologists to deliver non-invasive, accurate, and patient-centered prostate cancer diagnostics. By integrating Alpenglow’s whole-tissue 3D light-sheet imaging platform, the companies will enhance MRI-based predictions using high-resolution 3D microscope imagery that captures structural context and cellular details not visible through current imaging methods.
The project will generate a large-scale 3D dataset of human prostate tissue using light-sheet microscopy, with full cross-sections often exceeding 4 cm². This high-resolution dataset will serve as the foundation for assessing and refining Virdx’s MRI-based diagnostic models.
“This agreement reinforces the critical role of high-quality 3D pathology data in building the next wave of AI diagnostic tools,” said Nicholas Reder, M.D., MPH, CEO and Co-Founder of Alpenglow Biosciences.
“We are excited to partner with Alpenglow Biosciences,” said Jacob Murray, M.D., CEO and Co-Founder of Virdx. “Their innovative imaging technology helps us generate the essential data that powers our biophysics AI engine for MRI-based cancer diagnostics. Together, we aim to improve health outcomes and quality of life for patients.”
Using NVIDIA accelerated computing, Alpenglow and Virdx process multi-terabyte 3D microscopy datasets more than ten times faster than conventional CPU-based systems. This high-performance infrastructure enables the companies to collaborate on large-scale clinical studies. Alpenglow Biosciences is a member of NVIDIA Inception, a global program that supports cutting-edge AI startups.
